Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H14N4O4 |
Molecular Weight | 266.2533 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C2=C(N(CC3OCCO3)C=N2)C(=O)N(C)C1=O
InChI
InChIKey=HWXIGFIVGWUZAO-UHFFFAOYSA-N
InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
Molecular Formula | C11H14N4O4 |
Molecular Weight | 266.2533 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/?term=11268710Curator's Comment: description was created based on several sources, including
http://cathaydrug.ph/product/dilatair/
https://www.ncbi.nlm.nih.gov/pubmed/18376093
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=11268710
Curator's Comment: description was created based on several sources, including
http://cathaydrug.ph/product/dilatair/
https://www.ncbi.nlm.nih.gov/pubmed/18376093
Doxofylline (7-(1, 3-dioxalan-2-ylmethyl) theophylline) is a novel xanthine bronchodilator which differs from theophylline in that it contains a dioxalane group in position 7. Doxofylline is indicated for the treatment of bronchial asthma, pulmonary disease with spastic bronchial component and Chronic Obstructive Pulmonary Disease (COPD). Doxofylline does not directly inhibit any of the known HDAC enzymes, and did not inhibit any phosphodiesterase (PDE) enzyme sub types or act as an antagonist at any of the known adenosine receptors, except for PDE2A(1), and adenosine A(2A) and only at the highest tested concentration (10(-4) M). Doxofylline has greatly decreased affinity towards adenosine A1 and A2 receptors, which explain its better safety profile. Moreover, it does not interfere with calcium influx into the cells nor antagonize calcium channel blockers. Doxofylline has been shown to be a more potent bronchodilator with fewer side effects than theophylline. This drug should not be administered together with other xanthine derivatives, including beverages and foods containing caffeine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2652 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22138191 |
|||
Target ID: CHEMBL251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22138191 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Dilatair Approved UseUnknown |
|||
Palliative | Ddilatair Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects. | 2001 |
|
Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. | 2003 Sep 20 |
|
[Clinical study on doxofylline injection in treatment of children with acute asthma attacks]. | 2004 Feb |
|
[Effect of doxofylline on calcium-activated potassium channels in human peripheral blood eosinophils in asthma]. | 2005 Dec |
|
Preparation and bioavailability of sustained-release doxofylline pellets in beagle dogs. | 2008 Jul |
|
Doxofylline: The next generation methylxanthine. | 2008 Mar |
|
[Determination of levosimendan and its main metabolites in human plasma with HPLC-MS/MS method]. | 2008 Oct |
|
Spectrophotometric and reversed-phase high-performance liquid chromatographic method for the determination of doxophylline in pharmaceutical formulations. | 2010 Jul |
|
A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting β2 agonist in the treatment of moderate-to-severe persistent asthma. | 2010 Oct-Dec |
|
7-(1,3-Dioxolan-2-ylmethyl)-1,3-di-methyl-2,6-dioxo-2,3,6,7-tetra-hydro-1H-purin-9-ium tetra-chloridoferrate(III). | 2010 Sep 11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://cathaydrug.ph/product/dilatair/
Elderly Patients: 200 mg tablet two or three times daily.
Adults: 400 mg tablet two or three times daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2776832
Curator's Comment: Doxofylline inhibited PAF-induced bronchoconstriction in vitro, and the concomitant generation of TXA2-like activity in perfused guinea-pig lungs.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 02:04:54 UTC 2023
by
admin
on
Thu Jul 06 02:04:54 UTC 2023
|
Record UNII |
MPM23GMO7Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR03DA11
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
399413
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
||
|
NCI_THESAURUS |
C744
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
||
|
WHO-ATC |
R03DA11
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7022968
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
69975-86-6
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
100000080795
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
50942
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
M4756
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | Merck Index | ||
|
959
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
MPM23GMO7Z
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
DB09273
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
CC-71
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
5156
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
759645
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
C029797
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
94714
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
DOXOFYLLINE
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
C76317
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL1527608
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
274-239-6
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY | |||
|
SUB06390MIG
Created by
admin on Thu Jul 06 02:04:54 UTC 2023 , Edited by admin on Thu Jul 06 02:04:54 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |